GO
Loading...

Vivus Inc

More

  • Nasdaq stocks posting largest volume increases Thursday, 18 Sep 2014 | 6:04 PM ET

    The shares fell$. 10 or 1.1 percent to $8.70. Eastern Virginia Bankshares Inc.: Approximately 150,700 shares changed hands, a 1,515.3 percent increase over its 65- day average volume. The shares fell$. 04 or. 6 percent to $6.21.

  • Rite Aid and Pier 1 are big market movers Thursday, 18 Sep 2014 | 5:25 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:. Rite Aid Corp., down $1.23 to $5.41. Pier 1 Imports Inc., down $2.88 to $12.66.

  • The drug, developed by Vivus Inc, is marketed in the United States and Canada by Auxilium Pharmaceuticals Inc. Vivus' stock was up about 13 percent at $4.40 in afternoon trading.

  • The drug was developed by Auxilium Pharmaceuticals Inc and Vivus Inc.. Vivus owns the worldwide development and commercial rights to Stendra for use in sexual dysfunction, with the exception of certain Asian countries in the Pacific Rim.

  • NEW YORK, Sept 18- U.S. stocks were higher in afternoon trading on Thursday, with the S&P 500 hitting a record peak a day after the U.S.

  • Most active Nasdaq-traded stocks Thursday, 18 Sep 2014 | 1:18 PM ET

    Apple Inc. rose. 2 percent to $101.79 with 35,902,100 shares traded. Facebook Inc. rose. 7 percent to $77.00 with 22,472,500 shares traded. Gilead Sciences Inc. rose 2.0 percent to $105.93 with 16,071,400 shares traded.

  • The drug, developed by Vivus Inc, is marketed in the United States and Canada by Auxilium Pharmaceuticals Inc. Vivus' stock was up about 13 percent at $4.40 in afternoon trading.

  • US STOCKS-Dow, S&P hit record as financials climb Thursday, 18 Sep 2014 | 1:14 PM ET

    NEW YORK, Sept 18- U.S. stocks were higher in afternoon trading Thursday, with the Dow and S&P 500 hitting fresh record highs after the U.S. Goldman Sachs, up 1.6 percent to $187.84, was the top boost to the Dow.

  • US STOCKS-S&P hits record on Fed support; financials lead Thursday, 18 Sep 2014 | 11:42 AM ET

    NEW YORK, Sept 18- U.S. stocks were rising in late morning trading on Thursday, with the S&P 500 hitting a record high a day after the U.S. However, the central bank's outlook included forecasts for higher-than-expected rates in 2015 and 2016, which helped financial stocks lead gains on Wall Street.

  • The largest percentage gainer on the New York Stock Exchange was Penn West Petroleum, up 11.54 percent, while the largest decliner was Pier 1 Imports, down 17.57 percent a day after it slashed its full-year earnings forecast.

  • *Futures up: Dow 44 pts, S&P 6 pts, Nasdaq 13 pts. NEW YORK, Sept 18- U.S. stocks were set to rise at the open on Thursday, with the S&P 500 on track to test resistance at its record high a day after the U.S.

  • FDA OKs faster-acting label for ED drug Stendra Thursday, 18 Sep 2014 | 8:21 AM ET

    Federal regulators have approved a new label for Vivus' impotence drug, stating that it becomes effective in half the time that the previous label had stated. But Vivus has sought a new label after finding in studies that some patients were able to have sex as little as 15 minutes.

  • Sept 18- An erectile dysfunction drug that reduces by half the time patients need to take the pill before sexual activity has been approved by the U.S. Food and Drug Administration.

  • Long-awaited diet pill gets U.S. approval Wednesday, 10 Sep 2014 | 9:00 PM ET

    Sept 10- A new diet pill Contrave got approval to be sold in the United States on Wednesday, only the third obesity treatment in more than a decade to win approval from the Food and Drug Administration.

  • WASHINGTON, Sept 9- Novo Nordisk's drug liraglutide appears effective in treating obesity, though safety questions remain, according to a preliminary assessment by reviewers at the U.S. Food and Drug Administration.

  • Lightning Round: Akamai, GE & more Tuesday, 15 Jul 2014 | 6:49 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Orexigen shares hit by FDA delay in obesity drug Wednesday, 11 Jun 2014 | 10:07 AM ET

    Orexigen Therapeutics shares fell 15 percent after the FDA delayed its decision on the drug pending post-marketing safety monitoring requirements.

  • Orexigen shares plunge on FDA diet-drug delay Wednesday, 11 Jun 2014 | 7:33 AM ET

    Orexigen Therapeutics said the FDA delayed a decision on its obesity drug by three months, sending the company's shares down about 19 percent.

  • June 11- Orexigen Therapeutics Inc said the U.S. Food and Drug Administration delayed a decision on the marketing application for its obesity drug by three months, sending the company's shares down about 19 percent in premarket trading.

  • Obesity game-changer? Why this time it's different Monday, 9 Jun 2014 | 12:45 PM ET

    An FDA decision on Orexigen's obesity drug, Contrave, is expected Wednesday, and analysts say its late arrival on market may help.